tradingkey.logo
tradingkey.logo
Search

Moleculin Biotech Inc - Completion Of Its Phase 1B/2 (Mb-106) Clinical Trial Evaluating Annamycin In Combination With Cytarabine

ReutersAug 27, 2025 12:48 PM
facebooktwitterlinkedin

- Moleculin Biotech Inc MBRX.O:

  • MOLECULIN BIOTECH INC - COMPLETION OF ITS PHASE 1B/2 (MB-106) CLINICAL TRIAL EVALUATING ANNAMYCIN IN COMBINATION WITH CYTARABINE

  • MOLECULIN BIOTECH INC - MEDIAN OS OF 15 MONTHS FOR COMPLETE REMISSION SUBJECTS IN STUDY

  • MOLECULIN BIOTECH INC - CLINICAL STUDY REPORT ANTICIPATED IN Q1 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI